{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:15:00Z","timestamp":1777670100075,"version":"3.51.4"},"reference-count":8,"publisher":"SAGE Publications","issue":"21-22","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1089\/hum.2020.29139.bfs","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T12:21:04Z","timestamp":1605615664000},"page":"1141-1143","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["\u201cProfoundly Saddened\u201d Lysogene Discloses Child's Death in Phase II\/III Trial"],"prefix":"10.1177","volume":"31","author":[{"given":"Alex","family":"Philippidis","sequence":"first","affiliation":[{"name":"Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"e_1_3_1_2_2","unstructured":"Lysogene. Lysogene provides update on the AAVance clinical trial evaluating LYS-SAF302 in patients with MPS IIIA. https:\/\/www.lysogene.com\/lysogene-provides-update-on-the-aavance-clinical-trial-evaluating-lys-saf302-in-patients-with-mps-iiia\/ (last accessed October18 2020)."},{"key":"e_1_3_1_3_2","unstructured":"Dyno Therapeutics. Dyno therapeutics enters collaboration and license agreement with roche to develop next-generation AAV gene therapy vectors for CNS diseases and liver-directed therapies. https:\/\/www.dynotx.com\/news\/press-releases\/dyno-therapeutics-enters-collaboration-and-license-agreement-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-cns-diseases-and-liver-directed-therapies\/ (last accessed October17 2020)."},{"key":"e_1_3_1_4_2","unstructured":"Voyager Therapeutics. Voyager therapeutics provides regulatory update on VY-HTT01 program. https:\/\/ir.voyagertherapeutics.com\/news-releases\/news-release-details\/voyager-therapeutics-provides-regulatory-update-vy-htt01-program (last accessed October18 2020)."},{"key":"e_1_3_1_5_2","unstructured":"Gardner J. FDA puts Voyager study on hold in latest gene therapy speed bump. BioPharma Dive. https:\/\/www.biopharmadive.com\/news\/voyager-huntington-gene-therapy-clinical-hold\/586920\/ (last accessed October18 2020)."},{"key":"e_1_3_1_6_2","unstructured":"Solid Biosciences. Solid Biosciences announces FDA lifts clinical hold on IGNITE DMD clinical trial. https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-announces-fda-lifts-clinical-hold-on-ignite-dmd-clinical-trial (last accessed October18 2020)."},{"key":"e_1_3_1_7_2","unstructured":"Biogen Inc. (BIIB) Q3 2020 Earnings Call Transcript. The Motley Fool. https:\/\/www.fool.com\/earnings\/call-transcripts\/2020\/10\/21\/biogen-inc-biib-q3-2020-earnings-call-transcript\/ (last accessed October23 2020)."},{"key":"e_1_3_1_8_2","unstructured":"U.S. Securities and Exchange Commission. Biogen Inc. Form 10-K Annual Report for the Fiscal Year Ended December 31 2018. https:\/\/www.sec.gov\/Archives\/edgar\/data\/875045\/000087504519000006\/biib-20181231x10k.htm (last accessed October23 2020)."},{"key":"e_1_3_1_9_2","unstructured":"Ori Biotech. Ori Biotech raises $30 million in series a financing to advance innovation in cell and gene therapy manufacturing. https:\/\/oribiotech.com\/news\/ori-biotech-raises-30-million-in-series-a-financing-to-advance-innovation-in-cell-and-gene-therapy-manufacturing (last accessed October17 2020)."}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2020.29139.bfs","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2020.29139.bfs","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2020.29139.bfs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:55:23Z","timestamp":1777449323000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2020.29139.bfs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":8,"journal-issue":{"issue":"21-22","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1089\/hum.2020.29139.bfs"],"URL":"https:\/\/doi.org\/10.1089\/hum.2020.29139.bfs","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}